Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.retram.2021.103309 http://scihub22266oqcxt.onion/10.1016/j.retram.2021.103309 34418758!8354804!34418758     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Curr+Res+Transl+Med 2021 ; 69 (4): 103309 Nephropedia Template TP {{tp|p=34418758|t=2021. Potential use of ivermectin for the treatment and prophylaxis of SARS-CoV-2 infection |pdf=|usr=}}{{34418758}} gab.com Text Potential use of ivermectin for the treatment and prophylaxis of SARS-CoV-2 infection JO: Curr Res Transl Med http://www.kidney.de/pget.php?&tw=1&pmid=34418758 #FOAvip PURPOSE OF THE STUDY: Currently no treatment has been proven to be efficacious for patients with early symptoms of COVID-19. Although most patients present mild or moderate symptoms, up to 5-10% may have a poor disease progression, so there is an urgent need for effective drugs, which can be administered even before the onset of severe symptoms, i.e. when the course of the disease is modifiable. Recently, promising results of several studies on oral ivermectin have been published, which has prompted us to conduct the present review of the scientific literature. METHODS: A narrative review has been carried out, focusing on the following four main topics: a) short-term efficacy in the treatment of the disease, b) long-term efficacy in the treatment of patients with post-acute symptoms of COVID-19, c) efficacy in the prophylaxis of the disease, and c) safety of ivermectin. RESULTS: The reviewed literature suggests that there seems to be sufficient evidence about the safety of oral ivermectin, as well as the efficacy of the drug in the early-treatment and the prophylaxis of COVID-19. CONCLUSIONS: In the view of the available evidence, the Frontline COVID-19 Critical Care Alliance (FLCCC) recommends the use of oral ivermectin for both prophylaxis and early-treatment of COVID-19. Further well-designed studies should be conducted in order to explore the efficacy and safety of invermectin at low and high doses, following different dosing schedules, in both, the short and long-term treatment. Twit Text FOAVip Potential use of ivermectin for the treatment and prophylaxis of SARS-CoV-2 infection ????Curr Res Transl Med http://www.kidney.de/pget.php?&tw=1&pmid=34418758 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34418758 #FOAvip English Wikipedia <ref>{{Cite pmid|34418758}}</ref> Potential use of ivermectin for the treatment and prophylaxis of SARS-CoV-2 infection #MMPMID34418758 Cobos-Campos R; Apinaniz A; Parraza N; Cordero J; Garcia S; Orruno E Curr Res Transl Med 2021[Oct]; 69 (4): 103309 PMID34418758show ga PURPOSE OF THE STUDY: Currently no treatment has been proven to be efficacious for patients with early symptoms of COVID-19. Although most patients present mild or moderate symptoms, up to 5-10% may have a poor disease progression, so there is an urgent need for effective drugs, which can be administered even before the onset of severe symptoms, i.e. when the course of the disease is modifiable. Recently, promising results of several studies on oral ivermectin have been published, which has prompted us to conduct the present review of the scientific literature. METHODS: A narrative review has been carried out, focusing on the following four main topics: a) short-term efficacy in the treatment of the disease, b) long-term efficacy in the treatment of patients with post-acute symptoms of COVID-19, c) efficacy in the prophylaxis of the disease, and c) safety of ivermectin. RESULTS: The reviewed literature suggests that there seems to be sufficient evidence about the safety of oral ivermectin, as well as the efficacy of the drug in the early-treatment and the prophylaxis of COVID-19. CONCLUSIONS: In the view of the available evidence, the Frontline COVID-19 Critical Care Alliance (FLCCC) recommends the use of oral ivermectin for both prophylaxis and early-treatment of COVID-19. Further well-designed studies should be conducted in order to explore the efficacy and safety of invermectin at low and high doses, following different dosing schedules, in both, the short and long-term treatment. |*COVID-19 Drug Treatment[MESH] |*Drug Repositioning[MESH] |Antiviral Agents/adverse effects/*therapeutic use[MESH] |COVID-19/prevention & control[MESH] |Case-Control Studies[MESH] |Dose-Response Relationship, Drug[MESH] |Humans[MESH] |Ivermectin/administration & dosage/adverse effects/pharmacology/*therapeutic use[MESH] |Meta-Analysis as Topic[MESH] |Multicenter Studies as Topic[MESH] |Practice Guidelines as Topic[MESH] |Protein Transport/drug effects[MESH] |RNA Viruses/drug effects[MESH] |Randomized Controlled Trials as Topic[MESH] |SARS-CoV-2/*drug effects[MESH] |Time Factors[MESH]Potential use of ivermectin for the treatment and prophylaxis of SARS-(epmc).pdf DeepDyve Pubget Overpricing